U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H15F3N4O3.C7H8O3S.H2O
Molecular Weight 594.56
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOSUFLOXACIN TOSYLATE MONOHYDRATE

SMILES

O.CC1=CC=C(C=C1)S(O)(=O)=O.NC2CCN(C2)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=C(F)C=C(F)C=C5)C(O)=O

InChI

InChIKey=SSULTCPIIYRGFQ-UHFFFAOYSA-N
InChI=1S/C19H15F3N4O3.C7H8O3S.H2O/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25;1-6-2-4-7(5-3-6)11(8,9)10;/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29);2-5H,1H3,(H,8,9,10);1H2

HIDE SMILES / InChI

Molecular Formula C7H8O3S
Molecular Weight 172.202
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H15F3N4O3
Molecular Weight 404.3426
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf

Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rats. Human data not available.

Originator

Curator's Comment: http://adisinsight.springer.com/drugs/800005704 | http://www.chemdrug.com/article/8/3285/16420748.html

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

6.3296641E11
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

6.3296641E11
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

6.645024E11
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

6.3296641E11
PubMed

PubMed

TitleDatePubMed
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
1996 Nov
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.
1996 Oct
[In vitro anti-MAC activities of new quinolones in focus (2)].
1996 Sep
Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
1999 Oct
The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.
2000 Jul
History of quinolones and their side effects.
2001
Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosilate.
2001 Dec
In vitro method for prediction of the phototoxic potentials of fluoroquinolones.
2001 Dec
In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
2002 Mar
Clinical assessment of tosufloxacin tosilate.
2002 Mar
Pharmacokinetics and safety assessment of tosufloxacin tosilate.
2002 Mar
Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
2002 Mar
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
2002 Mar
Alteration of constitutive apoptosis in neutrophils by quinolones.
2003 Jun
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.
2004 Apr
An unusual form of crystal-forming chronic interstitial nephritis following long-term exposure to tosufloxacin tosilate.
2004 Nov
[Study on the accumulation of fluoroquinolones in clinical isolates of susceptible and multi-drug-resistant Escherichia coli strains].
2005 Jan
Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones.
2005 Jul
Antimicrobial safety: focus on fluoroquinolones.
2005 Jul 15
In vitro activity of fluoroquinolones against Mycoplasma genitalium and their bacteriological efficacy for treatment of M. genitalium-positive nongonococcal urethritis in men.
2005 Nov 1
[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation].
2006 Dec
[Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibiotics in Gifu prefecture (2004)].
2006 Jun
[Effectiveness of switch therapy for peritonitis].
2007 Aug
[Susceptibility of clinical isolates from primary care clinics to oral antibacterial agents].
2007 Feb
Tosufloxacin tosilate-induced thrombocytopenic purpura.
2007 Jul
[A case of acute bronchitis caused by Neisseria meningitidis associated with HIV infection].
2007 Nov
[Sensitivity surveillance of Haemophilus influenzae isolates for several antibiotics in Gifu Prefecture (2006)].
2008 Aug
Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin.
2008 Jul
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
2008 Jun
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
2009
Fluoroquinolones reduce carrageenan-induced edema in rats and the involvement of the glucocorticoid receptor system.
2009 Apr
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009 Dec 2
Corneal deposits after topical tosufloxacin in a patient with poor tear secretion.
2009 Jan
Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery.
2009 Jun 18
[Efficacy of tosufloxacin in genital chlamydial infections].
2009 Oct
[Antibiotic susceptibility of blood-borne Streptococcus pneumoniae and efficacy assessment of respiratory quinolones using Monte Carlo simulation].
2010 Feb
Legionella pneumophila induces cathepsin B-dependent necrotic cell death with releasing high mobility group box1 in macrophages.
2010 Nov 22
Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines.
2010 Sep 20
Patents

Sample Use Guides

In general, for adults, take 2 to 3 tablets (300 to 450 mg of the active ingredient) a day, in 2 to 3 divided doses. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day. Osteomyelitis, arthritis: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 3 times a day. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day. Typhoid/paratyphoid fever: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 4 times a day for 14 days.
Route of Administration: Oral
The MIC90s of tosufloxacin among the 27 isolates of macrolide-resistant Mycoplasma pneumoniae (MRMP) was 0.25 ug/ml and those among the 23 isolates of macrolide-sensitive Mycoplasma pneumoniae (MSMP) was 0.5 μg/ml.
Substance Class Chemical
Created
by admin
on Sat Dec 16 04:36:34 UTC 2023
Edited
by admin
on Sat Dec 16 04:36:34 UTC 2023
Record UNII
5L69LG8ZDQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOSUFLOXACIN TOSYLATE MONOHYDRATE
Common Name English
TOSUFLOXACIN TOSILATE HYDRATE
JAN  
Common Name English
TOSUXACIN
Brand Name English
Tosufloxacin tosilate monohydrate [WHO-DD]
Common Name English
TOSUFLOXACIN TOSILATE MONOHYDRATE
WHO-DD  
Common Name English
TOSUFLOXACIN TOSILATE HYDRATE [JAN]
Common Name English
OZEX
Brand Name English
Code System Code Type Description
SMS_ID
100000164913
Created by admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
PRIMARY
EVMPD
SUB179549
Created by admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
PRIMARY
CHEBI
32248
Created by admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
PRIMARY
CAS
1400591-39-0
Created by admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
PRIMARY
PUBCHEM
5282468
Created by admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
PRIMARY
FDA UNII
5L69LG8ZDQ
Created by admin on Sat Dec 16 04:36:34 UTC 2023 , Edited by admin on Sat Dec 16 04:36:34 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY